Seliger C, et al. - Researchers performed a pooled analysis of patient data from 1,731 individuals from the randomized AVAGlio, CENTRIC and CORE trials to examine the association between metformin use and survival. Multivariate COX-analyses were performed for overall survival (OS) and progression-free survival (PFS) comparing patients’ use of metformin at baseline and/or during concomitant radio-chemotherapy (TMZ/RT). As per outcomes, metformin alone or in any combination was not significantly associated with prolonged survival of patients with newly diagnosed glioblastoma.